Xenon Inhalation for Treatment of Posttraumatic Stress Disorder

A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Posttraumatic Stress Disorder

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with PTSD.

Inclusion Criteria:

• Patients with a current diagnosis of PTSD (documented diagnosis of PTSD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5] criteria and a Clinician Administered PTSD Scale [CAPS-5] total severity score of >30).
• Male and female patients between the ages of 18 and 85 years.

Exclusion Criteria:

• History of schizophrenia, bipolar and other psychotic disorders.
• Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma or any other respiratory conditions / diseases that may affect the respiratory function.
• Currently undergoing PTSD-targeted psychotherapy.
• Currently undergoing exposure-based psychotherapy for any condition.